{
  "id": 590092,
  "title": "Did Exelixis use a 'trivial' modification to its cash cow to product hop past a patent cliff? These researchers think so",
  "url": "https://urgent.news/2026/08/11/did-exelixis-use-a-trivial-modification-to-its-cash-cow-to-product",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-11T18:29:51.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/did-exelixis-use-a-trivial-modification-to-its-cash-cow-to-product-hop-past-a-patent-cliff-these-researchers-think-so/"
  },
  "original_language": "en",
  "account": null,
  "summary": "When Exelixis CEO Michael Morrissey rolled out the biotech's final numbers for 2025 earlier in the year, there was no mistaking the outsized role that cabozantinib played in funding the company and keeping its stock ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}